We are very grateful to the following corporate partners for all they do to support our work and our community.
Sepul Bio is a business unit within Thea exclusively focused on developing treatments for inherited retinal diseases. Sepul Bio’s initial focus will be to develop two flagship assets: Sepofarsen and Ultevursen. Sepofarsen is an investigational RNA therapy targeting Leber congenital amaurosis 10. This therapy is designed to address vision problems by addressing the underlying genetic mutation. Sepofarsen aims to skip aberrant mutation in the mRNA, leading to the production of functional protein. Ultevursen, also based on RNA technology, is aimed at addressing vision loss in Usher syndrome type 2a and non-syndromic retinitis pigmentosa.
Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has established a new focus on Retinal Diseases to develop transformational therapies and platforms that restore and preserve vision. This new focus expands Johnson & Johnson’s already broad ophthalmic footprint, and includes a pipeline of innovative treatments for inherited retinal diseases and more common retinal diseases affecting millions of people worldwide.
Okuvision has developed the Okustim, which is designed for electrical stimulation of the retina in patients with retinitis
pigmentosa in an out-patient or home setting.
We’d love to hear from you if you are interested in working with us. We take a flexible and personalised approach to our relationships with corporate supporters – give our friendly fundraising team a call on 01280 815900 or email fundraising@RetinaUK.org.uk for an informal chat.